Oxford Nanopore Earnings Call Maps Path to Profitability

Oxford Nanopore Technologies PLC ((GB:ONT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Oxford Nanopore Technologies’ latest earnings call struck a cautiously optimistic tone, as management highlighted accelerating revenue growth, improving margins and tighter cost control while acknowledging that the business remains loss‑making. Executives framed FY25 as a pivotal year in proving the model’s scalability and argued that the company now has a clearer, more disciplined path to profitability despite execution and market risks.

Broad-Based Revenue Beat Signals Demand Strength

Oxford Nanopore reported FY25 revenue of £223.9m, representing 24.2% growth at constant currency and coming in ahead of its 20–23% guidance range. Management stressed that growth exceeded 20% in every region, underscoring resilient global demand for its sequencing platform despite macro and geopolitical headwinds.

Applied Markets Take Bigger Slice of the Pie

The most striking shift came from applied end markets, where clinical revenue surged about 59%, biopharma grew 30% and applied industrial climbed 27%, outpacing the 15% growth in research. Research still accounts for roughly 66% of sales, but applied markets now make up around 34%, signaling a steady pivot toward higher value, more durable customer segments.

Profitability Trend Improves, But Losses Persist

The adjusted EBITDA loss improved by £31.2m, a 26% year‑on‑year step forward that management framed as evidence of operating leverage starting to kick in. Even so, the company remains meaningfully in the red and is targeting adjusted EBITDA breakeven only in 2027 and cash flow breakeven in 2028, leaving several more years of losses for investors to absorb.

Margins Edge Up With More Upside Guided

Gross margin dynamics were another bright spot, with underlying “see‑through” margin improving by roughly 460 basis points versus FY24, putting the true run‑rate closer to about 61%. Reported FY25 gross margin came in at 58.6%, and management guided to 62% in FY26, implying continued product and mix‑driven margin expansion as the model matures.

Cash Cushion Remains Solid as Burn Narrows

Oxford Nanopore closed FY25 with £302.8m in cash and no debt, giving it a sizeable buffer to fund its path to breakeven. Net cash outflow stood at £101m but was reduced by about £50m year on year, and management reiterated its intention to maintain at least £100m of cash on the balance sheet as it approaches profitability.

Cost Control Anchors Operating Leverage Story

Adjusted operating expenses grew by only 1% in FY25, a notable slowdown that reflected two rounds of restructuring and tighter spending discipline. For FY26, the company expects adjusted OpEx to rise by just 0–5%, indicating that any new investment will be highly targeted and that margin expansion will rely partly on continued cost discipline.

Sharper Strategic Focus on High-Value Segments

Management completed a strategic review that narrowed the company’s attention to higher‑opportunity segments they size at roughly $13–14bn. Commercial and R&D resources have been reallocated toward initiatives with better returns, with the aim of driving faster, more sustainable growth and higher margins while trimming lower‑priority projects.

Manufacturing Scale and Inventory Discipline Improve

Roughly 70% of revenue now comes from flow cells and kits produced at the company’s own manufacturing facility, which supports margin enhancements and supply reliability. Inventory management also improved, with inventories reduced by £18m and assets at customer sites down £10.5m as the business leans further into a CapEx‑first pricing model.

Scientific Track Record Underpins Market Adoption

Oxford Nanopore highlighted a decade of DNA products and around five years of direct RNA offerings, supported by approximately 20,000 publications that management says validate its differentiation. High‑profile applications, including use by NASA and UK Biobank’s plan to sequence 50,000 samples, were cited as proof points of scientific relevance and commercial potential.

Losses and Cash Outflows Still a Central Risk

Despite visible improvement, the company posted an operating loss before restructuring of £79.1m in FY25 and a net cash outflow of £101m, underlining that the business is still consuming capital. Management reaffirmed that adjusted EBITDA breakeven is not expected until 2027 and cash flow breakeven until 2028, leaving execution risk over multiple years.

One-Off Headwinds Mask Stronger Underlying Margins

Reported gross margin was depressed by several one‑off items, including obsolete inventory charges that shaved about 150 basis points off margin and foreign‑exchange headwinds costing around 70 basis points. An unfavorable product and customer mix also weighed by roughly 130 basis points, combining to pull the reported margin down to 58.6% despite stronger underlying economics.

Restructurings and Product Cuts Bring Near-Term Pain

Two restructuring events in FY25 drove total charges of £13.8m and contributed to short‑term disruption, though management argued they were necessary for long‑term efficiency. The commercial discontinuation of P2 Solo and the pause or withdrawal of the ElysION project also create transitional headwinds and execution risk as customers and internal teams adjust.

Product Roadmap Slippage May Delay Upside

Investors will note the re‑timing of the PromethION product roadmap, with key launches now expected only in late 2027. That delay pushes out some of the anticipated revenue and margin benefits from what is seen as a core high‑throughput platform, potentially tempering near‑term enthusiasm despite stronger current trends.

Regional Pressures in China and Wider APAC

The company flagged specific challenges in China, where export controls have created order backlogs and recognition delays, alongside intensifying local competition. The termination of the PRECISE II contract in the broader APAC region adds another headwind, contributing to a more cautious near‑term outlook for that geography even as growth remains broad‑based elsewhere.

Recycling and Working Capital Remain Moving Parts

MinION flow cell recycling was lower in FY25, offsetting gains from PromethION recycling and tempering the margin benefit that recycling can bring, with management noting that recycling volumes can be volatile. Meanwhile, although reported inventory fell by £18m, gross inventory remains elevated and will require continued active management to unlock additional cash over the coming years.

Product Transitions Create Short-Term Revenue Risk

The shift from P2 Solo to the newer P2i platform introduces conversion risk, as not all customers may transition on the expected timeline or at the anticipated scale. Management has built downside from incomplete conversion into its guidance, but the transition could still generate near‑term softness in device placements and related revenues as the installed base resets.

Guidance Points to Strong Growth and Margin Expansion

Looking ahead, management guided to FY26 revenue growth of 21–25% at constant currency, a gross margin target of 62% and adjusted OpEx growth capped at 0–5%, reaffirming targets for adjusted EBITDA breakeven in 2027 and cash flow breakeven in 2028 with a minimum cash buffer above £100m. The outlook assumes continued above‑market growth in clinical, biopharma and applied industrial segments, stronger momentum in the Americas, incremental margin gains from PromethION recycling and the CapEx‑first model, and incorporates regional headwinds in EMEA and APAC within the guidance range.

Oxford Nanopore’s earnings call portrayed a company moving convincingly toward scale, with broad‑based revenue growth, rising margins and firmer cost controls supporting a credible path to profitability. While ongoing losses, product delays and regional pressures mean execution risk remains high, management’s discipline and robust cash position give investors a clearer framework for judging progress over the next several years.